07:00 , Apr 16, 2012 |  BC Week In Review  |  Financial News

Avir Green completes venture financing

Avir Green Hills Biotechnology AG , Vienna, Austria   Business: Infectious, Cancer   Date completed: 3/30/12   Type: Venture financing   Raised: Not disclosed   Note: The company raised an undisclosed amount in a convertible...
07:00 , Apr 9, 2012 |  BC Week In Review  |  Clinical News

Seasonal deltaFLU: Phase I/II data

A Phase I/II trial in adults showed that the deltaFLU vaccine was well tolerated and induced immune responses against all 3 vaccine strains. Avir Green Hills Biotechnology AG , Vienna, Austria   Product: Seasonal deltaFLU...
08:00 , Jan 18, 2010 |  BC Week In Review  |  Clinical News

Seasonal H1N1 deltaFLU: Phase I data

Data from a placebo-controlled Phase I trial in 48 healthy volunteers showed that escalating doses of Avir Green Hills' intranasal seasonal H1N1 deltaFLU vaccine were safe and well tolerated. The vaccine induced immune responses and...
08:00 , Jan 18, 2010 |  BC Week In Review  |  Clinical News

Seasonal H1N1 deltaFLU: Phase II started

Avir began a double-blind, Austrian Phase II trial to evaluate intranasal Seasonal H1N1 deltaFLU in 48 healthy volunteers. Avir Green Hills Biotechnology AG , Vienna, Austria   Product: Seasonal H1N1 deltaFLU (formerly deltaFLU Envax )...
07:00 , Jun 29, 2009 |  BC Week In Review  |  Clinical News

Avir Green preclinical data

Data published in PLoS One showed that ferrets and mice vaccinated with intranasal deltaFLU Envax were protected from infection with influenza H5 viruses of various different clades. In macaques, 1 dose of the vaccine was...
07:00 , May 4, 2009 |  BioCentury  |  Product Development

Vaccine Manufacturing Technologies

Vaccine Manufacturing Technologies Company Vaccine manufacturing technology Avir Green Hills Biotechnology AG deltaFLU technology uses tissue cultures to produce vaccine Bacilligen Inc. Bacterial cells Baxter International Inc. (NYSE:BAX) Vero cells Crucell N.V. (Euronext:CRXL; NASDAQ:CRXL) /...
07:00 , Jul 21, 2008 |  BC Week In Review  |  Clinical News

Fluvacc: Phase I started

Avir began a double-blind, Austrian Phase I trial in healthy volunteers. Avir Green Hills Biotechnology AG , Vienna, Austria   Product: Fluvacc   Business: Infectious   Molecular target: Not applicable   Description: Influenza vaccine lacking...
07:00 , May 21, 2007 |  BC Week In Review  |  Clinical News

Fluvacc: Phase I started

Avir began an Austrian Phase I trial of intranasal Fluvacc in 24 healthy male volunteers. Avir Green Hills Biotechnology AG , Vienna, Austria   Product: Fluvacc   Business: Infectious   Molecular target: NA   Description:...
07:00 , Apr 23, 2007 |  BC Week In Review  |  Clinical News

Envax: Phase I start

Avir began a Phase I trial of intranasal Envax in 24 healthy male volunteers. Avir Green Hills Biotechnology AG , Vienna, Austria   Product: Envax   Business: Infectious   Molecular target: NA   Description: Replication-defective...